Health economics and outcomes research (HEOR)
Real-world evidence (RWE)-based treatment publications to meet the growing value-based pricing, market access, and reimbursement requirements.
HEOR publications to guide managed care decisions
Increased focus on value-based pricing means that life sciences companies need to embrace the “volume-to-value” shift in their organizational DNA. The pressure to systematically demonstrate RWE-based value as medical publications is more significant than ever before – critical to ensuring desired pricing, coverage, and reimbursement throughout the product’s lifecycle.
A sound HEOR capability is crucial for publication planning to guide decision-makers on meeting global patient-access demands.
Benefits
Fully customizable and transparent cost-effectiveness model for a pre-launch drug.
A budget impact model to assess the financial consequences of drug adoption from payers’ perspective.
Estimated RWE-based disease prevalence for granular patient segments using an optimization algorithm.
Differentiated modeling studies
- Deep understanding and experience of diverse data sets
- Deep therapeutic area expertise
- A team of experienced modelers, statisticians, and academic writers
- Extensive HEOR/RWE modeling experience
- Proactive engagement with key stakeholders to design easily scalable and adaptable models
- Statistically robust and clinically sound models
- Design solutions that can withstand scrutiny during evidence dissemination
- Continuous efforts towards implementing disruptive modeling approaches
Customer success stories
Case Study
Automated Email Campaigns Support The Patient Assistance Journey For Enhanced Treatment Outcomes
Case Study
Patient Flow Analysis For A Global Oncology Leader
Case Study